Recipharm AB (publ) logo

RECI B - Recipharm AB (publ) Share Price

SEK232.6 0.0  0.0%

Last Trade - 05/03/21

Mid Cap
Market Cap £2.03bn
Enterprise Value £2.79bn
Revenue £949.6m
Position in Universe th / 1831
Unlock RECI B Revenue
Relative Strength (%)
1m -1.97%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
3,389 4,678 5,332 6,374 7,457 11,069 11,972 12,706 +26.7%
+14.4 -13.9 +43.2 +13.8 +35.9 +39.1
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020,Recipharm AB (publ) revenues increased 48% to SEK11.07B.Net income applicable to common stockholders decreased 1%to SEK338.7M. Revenues reflect an increase in demand forthe Company's products and services due to favorable marketconditions. Net income was offset by Employee benefitsexpense increase of 42% to SEK3.66B (expense), Interestexpenses.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


RECI B Revenue Unlock RECI B Revenue

Net Income

RECI B Net Income Unlock RECI B Revenue

Normalised EPS

RECI B Normalised EPS Unlock RECI B Revenue

PE Ratio Range

RECI B PE Ratio Range Unlock RECI B Revenue

Dividend Yield Range

RECI B Dividend Yield Range Unlock RECI B Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
RECI B EPS Forecasts Unlock RECI B Revenue
Profile Summary

Recipharm publ AB is a Sweden-based pharmaceutical company, operating as a Contract Development and Manufacturing Organization (CDMO). It is divided in two business areas: Manufacturing Services, supplying a range of pharmaceutical products in different dosage forms, such as solid dose, semi solids, beta-lactams, hormones, dry powder metered dose inhalers, oral liquids and granulates, among others; and Development and Technology, offering clinical supply, product development, formulation, analytical development, stability studies, packaging development and raw material selection, as well as regulatory advice. It is also engaged in the development of own product portfolio. The Company targets two customer segments: large pharmaceutical companies, outsourcing part of their production; and small and medium-sized enterprises, outsourcing manufacturing and development services. Recipharm publ AB operates as a parent entity of the Recipharm Group, comprising approximately 15 subsidiaries.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since April 3, 2014
No. of Shareholders: n/a
No. of Employees: 7,383
Sector Healthcare
Industry Pharmaceuticals
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 101,485,683
Free Float (0.0%)
Eligible for
RECI B Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for RECI B
Upcoming Events for RECI B
Frequently Asked Questions for Recipharm AB (publ)
What is the Recipharm AB (publ) share price?

As of 05/03/21, shares in Recipharm AB (publ) are trading at SEK232.6, giving the company a market capitalisation of £2.03bn. This share price information is delayed by 15 minutes.

How has the Recipharm AB (publ) share price performed this year?

Shares in Recipharm AB (publ) are currently trading at SEK232.6 and the price has moved by 98.35% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Recipharm AB (publ) price has moved by 53.7% over the past year.

What are the analyst and broker recommendations for Recipharm AB (publ)?

Of the analysts with advisory recommendations for Recipharm AB (publ), there are there are currently 1 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Recipharm AB (publ) is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Recipharm AB (publ) next release its financial results?

Recipharm AB (publ) is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Recipharm AB (publ) dividend yield?

Recipharm AB (publ) does not currently pay a dividend.

Does Recipharm AB (publ) pay a dividend?

Recipharm AB (publ) does not currently pay a dividend.

When does Recipharm AB (publ) next pay dividends?

Recipharm AB (publ) does not currently pay a dividend.

How do I buy Recipharm AB (publ) shares?

To buy shares in Recipharm AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Recipharm AB (publ)?

Shares in Recipharm AB (publ) are currently trading at SEK232.6, giving the company a market capitalisation of £2.03bn.

Where are Recipharm AB (publ) shares listed? Where are Recipharm AB (publ) shares listed?

Here are the trading details for Recipharm AB (publ):

Country of listing: Sweden
Exchange: STO
Ticker Symbol: RECI B
What kind of share is Recipharm AB (publ)?

We were not able to load our ranking data for Recipharm AB (publ)

Is there a Recipharm AB (publ) share price forecast 2021?

Shares in Recipharm AB (publ) are currently priced at SEK232.6. At that level they are trading at 1.98% premium to the analyst consensus target price of 0.00.

Analysts covering Recipharm AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of 5.943 for the next financial year.

How can I tell whether the Recipharm AB (publ) share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Recipharm AB (publ). Over the past six months, the relative strength of its shares against the market has been 36.06%. At the current price of SEK232.6, shares in Recipharm AB (publ) are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Recipharm AB (publ) PE Ratio?

The Recipharm AB (publ) PE ratio based on its reported earnings over the past 12 months is 53.2. The shares are currently trading at SEK232.6.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Recipharm AB (publ)?

We were unable to find the directors for Recipharm AB (publ).

Who are the major shareholders of Recipharm AB (publ)?

Here are the top five shareholders of Recipharm AB (publ) based on the size of their shareholding:

AMF Pensionsförsäkring AB Pension Fund
Percentage owned: 6.02% (4.80m shares)
AFA Försäkring AB Insurance Company
Percentage owned: 5.77% (4.61m shares)
Flerie Participation AB Corporation
Percentage owned: 5.73% (4.57m shares)
Lannebo Fonder AB Investment Advisor/Hedge Fund
Percentage owned: 5.58% (4.45m shares)
Samson Rock Capital LLP Hedge Fund
Percentage owned: 5.04% (4.03m shares)
Similar to RECI B
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.